Twist Bioscience Corp (TWST)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $6.96B
Last updated: Nov 17, 2026 at 4:43 PM ET
Twist Bioscience Corp (TWST) Statistics
Twist Bioscience (TWST) has a market cap of $6.96B and an enterprise value of $6.43B. It kept -28.34% of revenue as net income over the last 12 months. Revenue grew 22.00% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 7.67% below the market cap, as cash exceeds debt.
| Market Cap | $6.96B |
|---|---|
| Enterprise Value | $6.43B |
| Latest price (Nov 17, 2026) | $112.00 |
Key Dates
The next earnings report is expected on Feb 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 12, 2026 |
| Fiscal Year End | September |
Valuation Ratios
Sales and book value multiples are 15.3x and 7.9x. Its year-end P/S ranged from 4.9x to 59.8x from 2018 to 2025.
| P/S Ratio | 15.3x |
|---|---|
| Forward P/S | 12.5x |
| P/B Ratio | 7.9x |
| P/TBV Ratio | 9.1x |
Price Statistics
The stock is up 316.82% over 52 weeks and trades 25.09% below its 50-day average.
| Beta (1Y) | 2.87 |
|---|---|
| 52-Week Change | +316.82% |
| 1-Month Change | -19.87% |
| 3-Month Change | -21.34% |
| 6-Month Change | +126.26% |
| 5-Year Change | +28.60% |
| Total Return (1Y) | +316.82% |
| Total Return (3Y CAGR) | +67.07% |
| Total Return (5Y CAGR) | -0.03% |
| Return vs SPY (1Y) | +319.21% |
| Max Drawdown (1Y) | -48.76% |
| Max Drawdown (3Y) | -58.97% |
| Sharpe Ratio (1Y) | 1.76 |
| Correlation with SPY (1Y) | 0.47 |
| 50-Day Average | $149.51 |
| 200-Day Average | $93.88 |
| 52-Week Range | $25.23 to $219.71 |
| RSI (14 Days) | 39.6 |
| Average Volume (20 Days) | 2.48M |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 5.86x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 5.86x |
|---|---|
| Quick Ratio | 5.49x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -14.66% over the last 12 months, against a 5-year average of -27.13%.
| Return on Equity (ROE) | -14.66% |
|---|---|
| Return on Assets (ROA) | -11.61% |
| ROE (5Y Average) | -27.13% |
| ROA (5Y Average) | -21.34% |
| ROIC (5Y Average) | -27.19% |
| Asset Turnover | 0.52x |
| Inventory Turnover | 5.36x |
| Receivables Turnover | 6.79x |
| Cash Conversion Cycle | 87 days |
Scores
TWST has an Altman Z-Score of 16.84, in the safe zone above 2.99, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 16.84 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 4 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue was $459.43M over the last 12 months.
| Revenue | $459.43M |
|---|---|
| Revenue Growth (YoY) | +22.00% |
| Gross Profit | $240.80M |
| Operating Income | -$139.46M |
| Pretax Income | -$129.80M |
| Net Income | -$130.20M |
| EBITDA | -$112.12M |
| Reported EPS (TTM) | -$1.98 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 79.29% of the $1.12B in total assets.
| Cash and Equivalents | $533.99M |
|---|---|
| Total Debt | $0 |
| Net Cash | $533.99M |
| Net Cash Per Share | $8.53 |
| Working Capital | $611.41M |
| Shareholder Equity | $888.02M |
| Book Value Per Share | $14.18 |
| Tangible Book Value | $771.66M |
| Tangible Book Per Share | $12.32 |
| Total Assets | $1.12B |
| Total Liabilities | $233.79M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $47.58M of capital spending, operating cash flow left -$89.01M of free cash flow.
| Operating Cash Flow | -$41.43M |
|---|---|
| Capital Expenditures | $47.58M |
| Free Cash Flow | -$89.01M |
| FCF Per Share | -$1.34 |
| Depreciation and Amortization | $26.48M |
| Share Repurchases | $42.00K |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -30.35%, against a 5-year average of -68.21%.
| Gross Margin | 52.41% |
|---|---|
| Operating Margin | -30.35% |
| Pretax Margin | -28.25% |
| Net Margin | -28.34% |
| EBITDA Margin | -24.40% |
| FCF Margin | -19.37% |
| Gross Margin (5Y Average) | 44.75% |
| Operating Margin (5Y Average) | -68.21% |
| Net Margin (5Y Average) | -61.23% |
Growth
Revenue grew 23.30% a year over 3 years.
| Revenue Growth (3Y CAGR) | +23.30% |
|---|---|
| Revenue Growth (5Y CAGR) | +28.27% |
| Book Value Per Share Growth (2Y CAGR) | -15.20% |
| Tangible Book Per Share Growth (2Y CAGR) | -13.96% |
Dividends and Yields
TWST does not pay a dividend. Its free cash flow yield is -1.27%.
| FCF Yield | -1.27% |
|---|---|
| Buyback Yield | -6.31% |
| Shareholder Yield | -6.31% |
Peer Position
Against 8 similar companies, TWST has the 5th highest P/S.
P/S RatioPeer median 15.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +27.75%
| P/S Ratio | 15.3x vs 15.5x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | +22.00% vs +27.75% median |
Analyst Forecast
Consensus estimates put revenue growth at 19.75% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +19.75% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Overvalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TWST
What is TWST's market cap?
Twist Bioscience has a market cap of $6.96B. Its enterprise value, which adds debt and subtracts cash, is $6.43B.
How many shares of TWST are outstanding?
Twist Bioscience has 62.62M shares outstanding. The count is up 4.01% from a year earlier.
Does TWST pay a dividend?
No. Twist Bioscience does not pay a dividend.
How much debt does TWST have?
Twist Bioscience has $0 of total debt and $533.99M of cash and equivalents, a net cash position of $533.99M.
TWST pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts